Health Canada authorized Novavax's updated COVID-19 vaccine that protects against currently circulating variants of the virus ...

Shares of Moderna Inc. MRNA slipped 2.63% to $68.02 Thursday, on what proved to be an all-around favorable trading session ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and ...

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...

Moderna Inc (MRNA) stock saw a decline, ending the day at $69.86 which represents a decrease of $-2.13 or -2.96% from the prior close of $71.99. The stock opened at $72.19 and touched a low of $69.82 ...

Respiratory illnesses like influenza, COVID-19 and Respiratory Syncytial Virus (RSV) are known to spread more rapidly during ...

COVID-19 vaccine-associated myocarditis (C-VAM) has a mild initial clinical course, but myocardial injury is common, ...

Florida officials are issuing conflicting statements with the Centers for Disease Control and Prevention about COVID-19 ...

With the U.S. Food and Drug Administration and Centers for Disease Control and Prevention approval of new mRNA COVID-19 ...

Clinical decision-making can be difficult for patients with SMA due to the lack of clinical trials comparing treatment ...

Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, ...